Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy

E. Furfaro, A. Signori, C. Di Grazia, A. Dominietto, A. M. Raiola, S. Aquino, C. Ghiggi, A. Ghiso, R. Ungaro, E. Angelucci, C. Viscoli, M. Mikulska

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. OBJECTIVES: To characterize the assessment of the blood levels of isavuconazole and their association with efficacy and toxicity. METHODS: From January 2017 to May 2018, blood samples obtained from patients receiving isavuconazole were analysed for therapeutic drug monitoring. Factors influencing the blood concentrations of isavuconazole, such as weight, length of treatment, route of administration and results of selected liver function tests, were analysed in univariate and multivariate models. The receiver operating characteristic (ROC) curve was analysed to detect the best cut-off for isavuconazole toxicity. RESULTS: A total of 264 isavuconazole blood concentrations in 19 patients were analysed. The median value of isavuconazole concentration in all patients during the first 30 days of therapy was 3.69 mg/L (range 0.64-8.13 mg/L). A linear increase of 0.032 mg/L (range 0.023-0.041 mg/L) for each day of treatment (P = 0.002) was observed. In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed. Adverse events, mainly gastrointestinal, were reported in six patients (31.6%). Based on time-dependent and fixed-time ROC curve analysis, 4.87 mg/L and 5.13 mg/L, respectively, were the identified thresholds for toxicity. CONCLUSIONS: Isavuconazole was efficacious and well tolerated. Side effects, mainly gastrointestinal, were associated with prolonged administration and high serum levels.

Original languageEnglish
Pages (from-to)2341-2346
Number of pages6
JournalThe Journal of antimicrobial chemotherapy
Volume74
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Therapeutics
ROC Curve
isavuconazole
Mucormycosis
Triazoles
Aspergillosis
Drug Monitoring
Liver Function Tests
Serum
Multivariate Analysis
Weights and Measures

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. / Furfaro, E.; Signori, A.; Di Grazia, C.; Dominietto, A.; Raiola, A. M.; Aquino, S.; Ghiggi, C.; Ghiso, A.; Ungaro, R.; Angelucci, E.; Viscoli, C.; Mikulska, M.

In: The Journal of antimicrobial chemotherapy, Vol. 74, No. 8, 01.08.2019, p. 2341-2346.

Research output: Contribution to journalArticle

Furfaro, E. ; Signori, A. ; Di Grazia, C. ; Dominietto, A. ; Raiola, A. M. ; Aquino, S. ; Ghiggi, C. ; Ghiso, A. ; Ungaro, R. ; Angelucci, E. ; Viscoli, C. ; Mikulska, M. / Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. In: The Journal of antimicrobial chemotherapy. 2019 ; Vol. 74, No. 8. pp. 2341-2346.
@article{fcd44c7268b44112b95d4fb52a95be63,
title = "Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy",
abstract = "BACKGROUND: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. OBJECTIVES: To characterize the assessment of the blood levels of isavuconazole and their association with efficacy and toxicity. METHODS: From January 2017 to May 2018, blood samples obtained from patients receiving isavuconazole were analysed for therapeutic drug monitoring. Factors influencing the blood concentrations of isavuconazole, such as weight, length of treatment, route of administration and results of selected liver function tests, were analysed in univariate and multivariate models. The receiver operating characteristic (ROC) curve was analysed to detect the best cut-off for isavuconazole toxicity. RESULTS: A total of 264 isavuconazole blood concentrations in 19 patients were analysed. The median value of isavuconazole concentration in all patients during the first 30 days of therapy was 3.69 mg/L (range 0.64-8.13 mg/L). A linear increase of 0.032 mg/L (range 0.023-0.041 mg/L) for each day of treatment (P = 0.002) was observed. In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed. Adverse events, mainly gastrointestinal, were reported in six patients (31.6{\%}). Based on time-dependent and fixed-time ROC curve analysis, 4.87 mg/L and 5.13 mg/L, respectively, were the identified thresholds for toxicity. CONCLUSIONS: Isavuconazole was efficacious and well tolerated. Side effects, mainly gastrointestinal, were associated with prolonged administration and high serum levels.",
author = "E. Furfaro and A. Signori and {Di Grazia}, C. and A. Dominietto and Raiola, {A. M.} and S. Aquino and C. Ghiggi and A. Ghiso and R. Ungaro and E. Angelucci and C. Viscoli and M. Mikulska",
year = "2019",
month = "8",
day = "1",
doi = "10.1093/jac/dkz188",
language = "English",
volume = "74",
pages = "2341--2346",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy

AU - Furfaro, E.

AU - Signori, A.

AU - Di Grazia, C.

AU - Dominietto, A.

AU - Raiola, A. M.

AU - Aquino, S.

AU - Ghiggi, C.

AU - Ghiso, A.

AU - Ungaro, R.

AU - Angelucci, E.

AU - Viscoli, C.

AU - Mikulska, M.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - BACKGROUND: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. OBJECTIVES: To characterize the assessment of the blood levels of isavuconazole and their association with efficacy and toxicity. METHODS: From January 2017 to May 2018, blood samples obtained from patients receiving isavuconazole were analysed for therapeutic drug monitoring. Factors influencing the blood concentrations of isavuconazole, such as weight, length of treatment, route of administration and results of selected liver function tests, were analysed in univariate and multivariate models. The receiver operating characteristic (ROC) curve was analysed to detect the best cut-off for isavuconazole toxicity. RESULTS: A total of 264 isavuconazole blood concentrations in 19 patients were analysed. The median value of isavuconazole concentration in all patients during the first 30 days of therapy was 3.69 mg/L (range 0.64-8.13 mg/L). A linear increase of 0.032 mg/L (range 0.023-0.041 mg/L) for each day of treatment (P = 0.002) was observed. In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed. Adverse events, mainly gastrointestinal, were reported in six patients (31.6%). Based on time-dependent and fixed-time ROC curve analysis, 4.87 mg/L and 5.13 mg/L, respectively, were the identified thresholds for toxicity. CONCLUSIONS: Isavuconazole was efficacious and well tolerated. Side effects, mainly gastrointestinal, were associated with prolonged administration and high serum levels.

AB - BACKGROUND: Isavuconazole is the newest triazole antifungal approved for the treatment of invasive aspergillosis (IA) and invasive mucormycosis in adult patients. OBJECTIVES: To characterize the assessment of the blood levels of isavuconazole and their association with efficacy and toxicity. METHODS: From January 2017 to May 2018, blood samples obtained from patients receiving isavuconazole were analysed for therapeutic drug monitoring. Factors influencing the blood concentrations of isavuconazole, such as weight, length of treatment, route of administration and results of selected liver function tests, were analysed in univariate and multivariate models. The receiver operating characteristic (ROC) curve was analysed to detect the best cut-off for isavuconazole toxicity. RESULTS: A total of 264 isavuconazole blood concentrations in 19 patients were analysed. The median value of isavuconazole concentration in all patients during the first 30 days of therapy was 3.69 mg/L (range 0.64-8.13 mg/L). A linear increase of 0.032 mg/L (range 0.023-0.041 mg/L) for each day of treatment (P = 0.002) was observed. In multivariate analysis the association between the length of treatment and higher levels of isavuconazole (P < 0.001) and higher serum GGT and lower isavuconazole levels (P = 0.001) was confirmed. Adverse events, mainly gastrointestinal, were reported in six patients (31.6%). Based on time-dependent and fixed-time ROC curve analysis, 4.87 mg/L and 5.13 mg/L, respectively, were the identified thresholds for toxicity. CONCLUSIONS: Isavuconazole was efficacious and well tolerated. Side effects, mainly gastrointestinal, were associated with prolonged administration and high serum levels.

UR - http://www.scopus.com/inward/record.url?scp=85070118927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070118927&partnerID=8YFLogxK

U2 - 10.1093/jac/dkz188

DO - 10.1093/jac/dkz188

M3 - Article

C2 - 31119272

AN - SCOPUS:85070118927

VL - 74

SP - 2341

EP - 2346

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 8

ER -